Amid Wood­ford de­ba­cle, Im­muno­core cuts val­u­a­tion as it se­cures $74M from Gen­er­al At­lantic — re­port

Im­muno­core ap­pears to be the lat­est domi­no to fall around Neil Wood­ford’s de­ba­cle as it so­lic­its new back­ing at a dras­ti­cal­ly low­er val­u­a­tion.

Once a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.